Keyword Analysis & Research: checkmate 577

Keyword Analysis

Keyword Research: People who searched checkmate 577 also searched

Frequently Asked Questions

What is the Checkmate 577 trial?

The CheckMate 577 trial is a global, randomized, double-blind, placebo-controlled phase 3 trial.

Is checkmate 577 an adjuvant treatment for esophageal junction cancer?

The success of the CheckMate 577, achieved by ICIs therapy in an adjuvant setting, absolutely revolutionized the landscape of cancer treatment and provide a new standard of care, especially for patients with ESCC who are non-pCR status. 1. Kelly, R. J. et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J.

Does Checkmate 577 improve disease-free survival in patients with resected EC/gejc?

Background: In CheckMate 577 (NCT02743494), NIVO demonstrated a significant and clinically meaningful improvement in disease-free survival (DFS; primary endpoint) vs placebo (PBO) and was well tolerated in patients (pts) with resected (R0) stage II/III EC/GEJC who received neoadjuvant CRT and had residual pathologic disease.

Search Results related to checkmate 577 on Search Engine